| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
50,566 |
39,055 |
$3.09M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
40,833 |
23,778 |
$846K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,501 |
9,526 |
$490K |
| 90832 |
Psychotherapy, 30 minutes with patient |
11,301 |
4,760 |
$226K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
8,837 |
5,131 |
$149K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,317 |
1,860 |
$90K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,891 |
1,630 |
$80K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,849 |
1,021 |
$54K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,738 |
1,012 |
$42K |
| 92557 |
|
2,745 |
1,709 |
$38K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,886 |
2,084 |
$26K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
6,295 |
3,953 |
$21K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,511 |
865 |
$19K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,100 |
645 |
$17K |
| 90834 |
Psychotherapy, 45 minutes with patient |
426 |
166 |
$12K |
| 80305 |
|
2,191 |
1,093 |
$11K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,468 |
883 |
$10K |
| 82962 |
|
9,361 |
5,506 |
$10K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
559 |
508 |
$7K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
173 |
112 |
$6K |
| 81025 |
|
1,941 |
1,098 |
$6K |
| 99188 |
|
680 |
350 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
444 |
225 |
$2K |
| 81002 |
|
1,827 |
1,100 |
$2K |
| 90480 |
|
60 |
46 |
$2K |
| 90686 |
|
2,430 |
1,414 |
$1K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
46 |
27 |
$1K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
202 |
131 |
$1K |
| 0013A |
|
28 |
28 |
$1K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
41 |
24 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
132 |
115 |
$931.67 |
| 0134A |
|
44 |
30 |
$856.72 |
| 90473 |
|
54 |
29 |
$252.52 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
38 |
28 |
$198.28 |
| 87210 |
|
145 |
120 |
$146.55 |
| 90723 |
|
670 |
418 |
$120.44 |
| 90670 |
|
1,292 |
778 |
$111.56 |
| 99177 |
|
22 |
12 |
$100.78 |
| 90651 |
|
317 |
187 |
$51.15 |
| 1036F |
|
15,808 |
8,108 |
$21.01 |
| 90647 |
|
615 |
377 |
$20.56 |
| 90633 |
|
261 |
183 |
$15.61 |
| 1034F |
|
4,063 |
2,231 |
$14.83 |
| 90710 |
|
260 |
168 |
$10.17 |
| 90681 |
|
97 |
66 |
$10.07 |
| 91313 |
|
43 |
29 |
$0.19 |
| 90685 |
|
80 |
51 |
$0.15 |
| 90734 |
|
69 |
43 |
$0.13 |
| 90619 |
|
31 |
18 |
$0.12 |
| 91321 |
|
16 |
15 |
$0.08 |
| 90697 |
|
258 |
159 |
$0.05 |
| 90672 |
|
68 |
36 |
$0.02 |
| 90715 |
|
39 |
34 |
$0.01 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
4,250 |
2,578 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
2,001 |
1,056 |
$0.00 |
| 3074F |
|
15,658 |
8,604 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
1,060 |
566 |
$0.00 |
| 3079F |
|
4,493 |
2,487 |
$0.00 |
| 90677 |
|
91 |
66 |
$0.00 |
| 3008F |
|
22,992 |
12,246 |
$0.00 |
| 3075F |
|
2,003 |
1,112 |
$0.00 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
379 |
221 |
$0.00 |
| 3080F |
|
374 |
198 |
$0.00 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
27 |
14 |
$0.00 |
| 90680 |
|
36 |
33 |
$0.00 |
| 1035F |
|
21 |
13 |
$0.00 |
| 92551 |
|
26 |
14 |
$0.00 |
| 3044F |
|
44 |
27 |
$0.00 |
| 90696 |
|
14 |
13 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
57 |
32 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
5,609 |
3,080 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
3,459 |
2,076 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
1,097 |
651 |
$0.00 |
| 4004F |
|
1,976 |
1,041 |
$0.00 |
| 3078F |
|
14,015 |
7,723 |
$0.00 |
| 1160F |
|
17,016 |
8,513 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
4,749 |
2,589 |
$0.00 |
| 1159F |
|
17,015 |
8,511 |
$0.00 |
| 3725F |
|
9,345 |
4,957 |
$0.00 |
| 3077F |
|
1,465 |
751 |
$0.00 |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
40 |
37 |
$0.00 |
| 90671 |
|
112 |
69 |
$0.00 |
| 3046F |
|
43 |
24 |
$0.00 |